Effects of low-dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis: A meta-analysis

Journal of Investigative Medicine

Volumn 56, Issue 8, 2008, Pages 1011-1018

  Lee, Young Ho ^a   Woo, Jin Hyun ^a   Choi, Seong Jae ^a   Ji, Jong Dae ^a   Song, Gwan Gyu ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Bone mineral density; Corticosteroid; Rheumatoid arthritis

Indexed keywords

PLACEBO; PREDNISOLONE; CORTICOSTEROID;

ADULT; ARTICLE; BONE DENSITY; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; COCHRANE LIBRARY; CORTICOSTEROID THERAPY; DRUG EFFECT; FEMALE; FEMUR NECK; FOLLOW UP; HUMAN; LOW DRUG DOSE; LUMBAR VERTEBRA; MALE; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; RANDOMIZED CONTROLLED TRIAL;

ADRENAL CORTEX HORMONES; ARTHRITIS, RHEUMATOID; BONE DENSITY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 58149331421     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31818e82d7     Document Type: Article

References (28)

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990;322: 1277-1289.
2. Peel NF, Spittlehouse AJ, Bax DE, et al. Bone mineral density of the hand in rheumatoid arthritis. Arthritis Rheum. 1994;37:983-991.
3. Bhalla AK, Shenstone B. Bone densitometry measurements in early inflammatory disease. Baillieres Clin Rheumatol. 1992;6:405-414.
4. Laan RF, Buijs WC, Verbeek AL, et al. Bone mineral density in patients with recent onset rheumatoid arthritis: influence of disease activity and functional capacity. Ann Rheum Dis. 1993;52:21-26.
5. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med. 1995;333:142-146.
6. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, diseasemodifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002;136:1-12.
7. Choy EH, Kingsley GH, Khoshaba B, et al. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis. 2005;64:1288-1293.
8. Capell HA, Madhok R. Another DMARD option in rheumatoid arthritis? J Rheumatol. 2003;30:2085-2087.
9. Hansen M, Podenphant J, Florescu A, et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann Rheum Dis. 1999;58:713-718.
10. Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med. 1993;119:963-968.
11. Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005;52:3360-3370.
12. van Everdingen AA, Siewertsz van Reesema DR, Jacobs JW, et al. Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures? Clin Exp Rheumatol. 2003;21:155-160.
13. van Schaardenburg D, Valkema R, Dijkmans BA, et al. Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment. Arthritis Rheum. 1995;38:334-342.
14. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315:1533-1537.
15. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
16. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629-634.
17. Duval S, Tweedie R. Trim and fill: a simple funnelplot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455-463.
18. Corbett J, Gu CC, Rice JP, et al. Power loss for linkage analysis due to the dichotomization of trichotomous phenotypes. Hum Hered. 2004;57:21-27.
19. Davey Smith G, Egger M. Meta-analyses of randomised controlled trials. Lancet. 1997;350:1182.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
21. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
22. Chung CP, Russell AS, Segami MI, et al. The effect of low-dose prednisone on bone mineral density in Peruvian rheumatoid arthritis patients. Rheumatol Int. 2005;25: 114-117.
23. Habib GS, Haj S. Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids. Clin Rheumatol. 2005;24:129-133.
24. Miyamoto S, Kageyama Y, Ozeki T, et al. Effects of glucocorticoids on bone mineral density in rheumatoid arthritis patients. A longitudinal study. Arch Orthop Trauma Surg. 1999;119:18-21.
25. Sambrook PN, Eisman JA, Yeates MG, et al. Osteoporosis in rheumatoid arthritis: safety of low dose corticosteroids. Ann Rheum Dis. 1986;45:950-953.
26. Verhoeven AC, Boers M, te Koppele JM, et al. Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. Rheumatology (Oxford). 2001;40:1231-1237.
27. Verhoeven AC, Boers M. Limited bone loss due to corticosteroids; a systematic review of prospective studies in rheumatoid arthritis and other diseases. J Rheumatol. 1997;24:1495-1503.
28. Haugeberg G, Strand A, Kvien TK, et al. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med. 2005;165:1293-1297.